To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Prospective, interventional, open, randomized, national, multicenter, non-commercial trial

Trial Details

NCT ID
NCT05968768
Phase
PHASE2
Sponsor
Anna Raciborska
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Naxitamab
Locations (sample)
  • Warsaw, Mazowian, Poland|52.22977,21.01178
  • Wroclaw, Poland|51.10286,17.03006

Key Eligibility Criteria

  • Histologically proven Ewing sarcoma of the bone or soft tissues.
  • Subject's archival tumour sample (formalin-fixed, paraffin-embedded; FFPE) available for evaluation of GD2 expression.
  • Documented disease progression (during or after completion of at least one line treatment) or any subsequent recurrence.
  • GD2 positive tumor assessed by IHC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →